HC Wainwright Reaffirms Buy Rating for SABS
HC Wainwright maintains its optimistic outlook on SABS with a reiterated buy rating, a 200.30% upside from the current price.
Key Points
- HC Wainwright reiterated its buy rating for SABS on June 15, 2026, with a price target of $10.
- HC Wainwright's $10 price target implies 200.30% upside from SAB Biotherapeutics, Inc.'s ($SABS) current $3.33 share price.
- SABS shares traded at $3.33, reflecting ongoing analyst confidence despite current market conditions.
- Recent insider buying includes significant purchases by executives, with the CEO acquiring 4.8 million shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 15, 2026, HC Wainwright reiterated its buy rating for SABS, setting a price target of $10. Analyst Emily Bodnar expressed confidence in the company's prospects despite current market challenges. Shares of SABS were trading at $3.33 at the time of the rating.
Other Institutional Activity in SABS
Vivo Capital, LLC maintained its position in SABS, holding steady at 11.42 million shares valued at about $43.74 million. Caligan Partners LP established a new stake with 7.97 million shares worth approximately $30.51 million. Perceptive Advisors LLC significantly increased its holdings by 5.63 million shares, bringing its total to 6.43 million shares valued at $24.63 million. Meanwhile, RA Capital Management, L.P. and Commodore Capital LP held their positions steady, each with 4.40 million shares valued at $16.86 million.
SAB Biotherapeutics, Inc. Stock Down 12.1%
SABS shares are currently trading at $3.33. The stock has been receiving attention from several analysts, with a recent reiterated buy rating from HC Wainwright. While the company's market cap and other financial metrics were not detailed, the stock's price target suggests potential upside from its current trading level.
$SABS price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at SAB Biotherapeutics, Inc.
Recent insider transactions at SABS include significant purchases on February 3, 2026. Chief Financial Officer Lucy To and Chief Operating Officer Christoph Lawrence Bausch each acquired 2.4 million shares, while Chief Medical Officer Alexandra Kropotova and CEO Samuel Reich bought 2.4 million and 4.8 million shares, respectively. These transactions were not part of any pre-planned trading program.
Analysts Set New Price Targets
On June 15, 2026, HC Wainwright reiterated its buy rating for SABS with a $10 price target. Earlier, on May 22, 2026, Citigroup initiated coverage with a buy rating and an $11 target. Jefferies also started coverage with a buy rating and an $11 target on May 20, 2026. The consensus among analysts is positive, with a mean target price reflecting optimism about SABS's future performance.
Bottom Line
HC Wainwright's reiterated buy rating for SABS highlights continued analyst confidence in the company's potential, as reflected in its $10 price target. This optimism is mirrored by recent institutional activity, with significant stake increases by several funds. Insider buying by key executives further underscores confidence in SABS's prospects. As always, it's important to remember that analyst ratings and insider transactions are just part of the broader picture investors should consider.
Get SAB Biotherapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $SABS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.